Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase

被引：0

作者：

Skljarevski, Vladimir ^{[1
]}

Stauffer, Virginia L. ^{[1
]}

Zhang, Qi ^{[1
]}

Detke, Holland C. ^{[1
]}

Millen, Brian A. ^{[1
]}

Yang, Jyun Yan ^{[1
]}

Selzler, Katherine J. ^{[1
]}

Conley, Robert ^{[1
,2
]}

Aurora, Sheena K. ^{[1
]}

机构：

[1] Eli Lilly & Co, Indianapolis, IN 46285 USA

[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

来源：

CEPHALALGIA | 2017年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

PO-01-197

引用

页码：339 / 340

页数：2

共 50 条

[31] 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies (vol 58, pg 1347, 2018)
Rosen, N.
Pearlman, E.
Ruff, D.
Nagy, Jim A.
HEADACHE, 2019, 59 (08): : 1428 - 1428
[32] Analysis of Initial Non Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials
Nichols, Russell M.
Ruff, Dustin
Pearlman, Eric
Aurora, Sheena K.
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[33] Analysis of Initial Non-Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials
Nichols, R.
Ruff, D.
Pearlman, E.
Aurora, S.
HEADACHE, 2018, 58 : 173 - 174
[34] Persistence of Effect of Galcanezumab in Patients with Episodic or Chronic Migraine: Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1,-2 and REGAIN Studies
Aurora, S.
Zhang, Q.
HEADACHE, 2018, 58 : 177 - 178
[35] Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
Smitherman, Todd A.
Tietjen, Gretchen E.
Schuh, Kory
Skljarevski, Vladimir
Lipsius, Sarah
D'Souza, Deborah N.
Pearlman, Eric M.
HEADACHE, 2020, 60 (10): : 2202 - 2219
[36] Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial (vol 75, pg 1080, 2018)
Stauffer, V. L.
Dodick, D. W.
Zhang, Q.
Carter, J. N.
Ailani, J.
Conley, R. R.
JAMA NEUROLOGY, 2019, 76 (07) : 872 - 872
[37] Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial (vol 75, pg 1080, 2018)
Stauffer, V. L.
Dodick, D. W.
Zhang, Q.
Carter, J. N.
Ailani, J.
Conley, R. R.
JAMA NEUROLOGY, 2018, 75 (09) : 1156 - 1156
[38] Efficacy of galcanezumab for migraine prevention in patients with a medical history of anxiety and/or depression: a post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled REGAIN, and pooled EVOLVE-1 and EVOLVE-2 studies (vol 60, pg 2202, 2020)
Smitherman, T. A.
HEADACHE, 2022, 62 (01): : 114 - 116
[39] Treatment with Galcanezumab in Patients with Episodic Migraine: Results from the OpenLabel Phase of the PERSIST Study
Yu, Shengyuan
Zhou, Jiying
Zhuang, Junpeng
Liu, Hui
Qian, Chenxi
NEUROLOGY, 2023, 100 (17)
[40] A phase 3 placebo-controlled study of galcanezumab in patients with episodic migraine: Results from the 3-month double-blind treatment phase of the PERSIST study
Yu, S.
Hu, B.
Li, G.
Jia, Z.
Chowdhury, D.
Zhuang, J.
Qian, C.
HEADACHE, 2022, 62 : 130 - 131

← 1 2 3 4 5 →